Plasma metabolomics in human pulmonary tuberculosis disease: A pilot study

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Frediani, Jennifer K ^a,b   Jones, Dean P ^a,b   Tukvadze, Nestan ^c   Uppal, Karan ^b   Sanikidze, Eka ^c   Kipiani, Maia ^c   Tran, Vilinh T ^b   Hebbar, Gautam ^b   Walker, Douglas I ^b,d   Kempker, Russell R ^b   Kurani, Shaheen S ^b   Colas, Romain A ^e   Dalli, Jesmond ^e   Tangpricha, Vin ^a,b,f   Serhan, Charles N ^e   Blumberg, Henry M ^b,c,g   Ziegler, Thomas R ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Center for Tuberculosis and Lung Diseases   (Georgia)

^d Tufts University   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ATLANTA VA MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; BIOLOGICAL MARKER; CHOLINE DERIVATIVE; CORD FACTOR; GLUTAMIC ACID; PHOSPHATIDYLINOSITOL; RESOLVIN D1; RESOLVIN D2; UNCLASSIFIED DRUG; TUBERCULOSTATIC AGENT;

ADULT; AMINO ACID SYNTHESIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPIDOMICS; LUNG TUBERCULOSIS; MALE; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR PATHOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PILOT STUDY; PLASMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM ANALYSIS; UPREGULATION; BIOLOGY; BLOOD; DRUG INACTIVATION; METABOLISM; MICROBIOLOGY; PATHOGENICITY; SPUTUM; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; INACTIVATION, METABOLIC; MALE; METABOLOMICS; MYCOBACTERIUM TUBERCULOSIS; PILOT PROJECTS; SPUTUM; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84908048654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108854     Document Type: Article

References (65)

1. World Health Organization (2013) WHO Global Report.
2. Zumla A, George A, Sharma V, Herbert N, Baroness Masham of Ilton (2013) WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 382:1765-1767.
3. Zumla A, Raviglione M, Hafner R, von Reyn CF (2013) Tuberculosis. New England Journal of Medicine 368:745-755.
4. Maertzdorf J, Weiner JR, Kaufmann SH (2012) Enabling biomarkers for tuberculosis control. International Journal of Tuberculosis and Lung Disease 16:1140-1148.
5. Wallis RS, Kim PC, Cole S, Hanna D, Andrade BB, et al. (2013) Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infectious Disease 13:362-372.
6. Jones DP, Park Y, Ziegler TR (2012) Nutritional metabolomics: progress in addressing complexity in diet and health. Annual Review of Nutrition 32:183-202.
7. Park YH, Lee K, Soltow QA, Strobel FH, Brigham KL, et al. (2012) Highperformance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring. Toxicology 295:47-55.
8. Yu T, Park Y, Li S, Jones DP (2013) Hybrid feature detection and information accumulation using high-resolution LC-MS metabolomics data. Journal of Proteome Research 12:1419-1427.
9. Sonawat HM, Sharma S (2012) Host responses in malaria disease evaluated through nuclear magnetic resonance-based metabonomics. Clinics in Laboratory Medicine 32:129-142.
10. Sana TR, Gordon DB, Fischer SM, Tichy SE, Kitagawa N, et al. (2013) Global mass spectrometry based metabolomics profiling of erythrocytes infected with Plasmodium falciparum. PLoS One 8:e60840.
11. Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, et al. (2013) Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environmental Microbiology 15:398-408.
12. Cribbs SK, Park Y, Guidot DM, Martin GS, Brown LA, et al. (2014) Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls. AIDS Research and Human Retroviruses 30:579-585.
13. Seymour CW, Yende S, Scott MJ, Pribis J, Mohney RP, et al. (2013) Metabolomics in pneumonia and sepsis: an analysis of the GenIMS cohort study. Intensive Care Medicine 39:1423-1434.
14. Tian J, Bryk R, Itoh M, Suematsu M, Nathan C (2005) Variant tricarboxylic acid cycle in Mycobacterium tuberculosis: identification of alpha-ketoglutarate decarboxylase. Proceedings of the National Academy of Sciences of the United States of America 102:10670-10675.
15. Anishetty S, Pulimi M, Pennathur G (2005) Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Computational Biology and Chemistry 29:368-378.
16. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S (2010) Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proceedings of the National Academy of Sciences of the United States of America 107:9819-9824.
17. Eoh H, Rhee KY (2013) Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 110:6554-6559.
18. Loots DT (2014) An altered M. tuberculosis metabolome induced by katG mutations resulting in isoniazid-resistance. Antimicrobial Agents and Chemotherapy 58:2144-2149.
19. Shin JH, Yang JY, Jeon BY, Yoon YJ, Cho SN, et al. (2011) (1) H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis. Journal of Proteome Research 10:2238-2247.
20. Somashekar BS, Amin AG, Tripathi P, MacKinnon N, Rithner CD, et al. (2012) Metabolomic signatures in guinea pigs infected with epidemic-associated W-Beijing strains of Mycobacterium tuberculosis. Journal of Proteome Research 11:4876-4884.
21. Zhou A, Ni J, Xu Z, Wang Y, Lu S, et al. (2013) Application of 1H NMR spectroscopy-based metabolomics to sera of tuberculosis patients. Journal of Proteome Research 12:4642-4649.
22. du Preez I, Loots DT (2013) New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa. Tuberculosis (Edinb) 93:330-337.
23. Che N, Cheng J, Li H, Zhang Z, Zhang X, et al. (2013) Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung. Clinica Chimica Acta 423:5-9.
24. Weiner J, Parida SK, Maertzdorf J, Black GF, Repsilber D, et al. (2012) Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 7:e40221.
25. Desai NS, Tukvadze N, Frediani JK, Kipiani M, Sanikidze E, et al. (2012) Effects of sunlight and diet on vitamin D status of pulmonary tuberculosis patients in Tbilisi, Georgia. Nutrition 28:362-366.
26. Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK, et al. (2012) Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 7:e31563.
27. Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, et al. (2009) Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. International Journal of Tuberculosis and Lung Disease 13:68-73.
28. Frediani JK, Tukvadze N, Sanikidze E, Kipiani M, Hebbar G, et al. (2013) A culture-specific nutrient intake assessment instrument in patients with pulmonary tuberculosis. Clinical Nutrition 32:1323-1028.
29. Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, et al. (2013) High-performance metabolic profiling with dual chromatography-Fouriertransform mass spectrometry (DC-FTMS) for study of the exposome. Metabolomics 9:132-143.
30. Johnson JM, Yu T, Strobel FH, Jones DP (2010) A practical approach to detect unique metabolic patterns for personalized medicine. Analyst 135:2864-2870.
31. Dalli J, Serhan CN (2012) Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120:e60-e72.
32. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. American Journal of Physiology Cell Physiology 307:C39-54.
33. Yang R, Chiang N, Oh SF, Serhan CN (2011) Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Current Protocols in Immunology Chapter 14.
34. Spite M, Claria J, Serhan CN (2014) Resolvins, specialized pro-resolving lipid mediators, and their potential roles in metabolic disease. Cell Metabolism 19:21-36.
35. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510:92-101.
36. Uppal K, Soltow QA, Strobel FH, Pittard WS, Gernert KM, et al. (2013) xMSanalyzer: automated pipline for improved feature detection and downstream analyisis of large-scale, non-targeted metabolomics data. BMC Bioinformatics 14.
37. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman VCR, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York. pp. 397-420.
38. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Statistics in Medicine 9:811-818.
39. Scalbert A, Brennan L, Fiehn O, Hankemeier T, Kristal BS, et al. (2009) Massspectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics 5:435-458.
40. Roede JR, Uppal K, Park Y, Lee K, Tran V, et al. (2013) Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS One 8:377629.
41. Osborn MP, Park Y, Parks MB, Burgess LG, Uppal K, et al. (2013) Metabolome-wide association study of neovascular age-related macular degeneration. PLoS One 8:e72737.
42. Smith CA, O-Maille G, Want EJ, Qin C, Trauger SA, et al. (2005) METLIN: a metabolite mass spectral database. Therapeutic Drug Monitoring 27:747-751.
43. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1:29-34.
44. Wishart DS, Knox C, Guo AC, Eisner R, Young N, et al. (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37:D603-610.
45. Godfrey AR, Brenton AG (2012) Accurate mass measurements and their appropriate use for reliable analyte identification. Analytical and Bioanalytical Chemistry 404:1159-1166.
46. Levy BD, Serhan CN (2014) Resolution of acute inflammation in the lung. Annual Review of Physiology 76:467-492.
47. Brennan PJ, Crick DC (2007) The cell-wall core of Mycobacterium tuberculosis in the context of drug discovery. Current Topics in Medicinal Chemistry 7:475-488.
48. Esko JC, Doering TL, Raetz CRH (2009) Eubacteria and Archaea. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, et al., editors. Essentials of Glycobiology. 2nd ed. New York: Cold Spring Harbor Laboratory Press.
49. Worley B, Halouska S, Powers R (2013) Utilities for quantifying separation in PCA/PLS-DA scores plots. Analytical Biochemistry 433:102-104.
50. Li FM, Miao Y, Zhang L, Neuenswander SA, Douglas JT, et al. (2011) Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine. Drug Metabolism and Pharmacokinetics 26:569-576.
51. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, et al. (2006) CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. European Journal of Clinical Pharmacology 62:423-429.
52. Rivera-Betancourt OE, Karls R, Grosse-Siestrup B, Helms S, Quinn F, et al. (2013) Identification of mycobacteria based on spectroscopic analyses of mycolic acid profiles. Analyst 138:6774-6785.
53. Marrakchi H, Lanéelle MA, Daffé M (2014) Mycolic acids: structures, biosynthesis, and beyond. Chemistry and Biology 21:67-85.
54. Dobson CM, Hempel SJ, Stalnaker SH, Stuart R, Wells L (2013) O-Mannosylation and human disease. Cellular and Molecular Life Sciences 70:2849-2857.
55. Rivera-Marrero CA, Ritzenthaler JD, Newburn SA, Roman J, Cummings RD (2002) Molecular cloning and expression of a novel glycolipid sulfotransferase in Mycobacterium tuberculosis. Microbiology 148:783-792.
56. Patterson JH, Waller RF, Jeevarajah D, Billman-Jacobe H, McConville MJ (2003) Mannose metabolism is required for mycobacterial growth. Biochemical Journal 372:77-86.
57. Lyon RH, Hall WH, Costas-Martinez C (1970) Utilization of amino acids during growth of Mycobacterium tuberculosis in rotary cultures. Infection and Immunity 1:513-520.
58. Wietzerbin J, Lederer F, Petit JF (1975) Structural study of the poly-l-Glutamic acid of the cell wall of Mycobacterium tuberculosis var hominis, strain Brevannes. Biochemical and Biophysical Research Communications 62:246-252.
59. Peregrín-Alvarez JM, Sanford C, Parkinson J (2009) The conservation and evolutionary modularity of metabolism. Genome Biology 10:R63.
60. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, et al. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. Journal of Experimental Medicine 196:1025-1037.
61. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, et al. (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proceedings of the National Academy of Sciences of the United States of America 107:1660-1665.
62. Spite M, Norling LV, Summers L, Yang R, Cooper D, et al. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461:1287-1291.
63. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, et al. (2012) Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148:434-446.
64. Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD (2012) Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radical Biology and Medicine 53:160-171.
65. Mas E, Croft KD, Zahra P, Barden A, Mori TA (2012) Resolvins D1, D2 and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clinical Chemistry 58:1476-1484.